Back to today’s briefing

Story perspectives

Myriad Genetics Projects Earnings Amid Analyst "Hold" Rating

2/18/2025

28 7

Summary

Story summary

Myriad Genetics (NASDAQ:MYGN) is set to unveil its quarterly earnings on February 25, projecting earnings of $0.03 per share and revenue of $210.35 million. The stock opened at $14.56, boasting a market cap of $1.33 billion. Analysts maintain a "Hold" rating, eyeing an average target price of $22.54 for this leader in genetic testing and precision medicine.

1 of 1

Story summary

Myriad Genetics (NASDAQ:MYGN) is set to unveil its quarterly earnings on February 25, projecting earnings of $0.03 per share and revenue of $210.35 million. The stock opened at $14.56, boasting a market cap of $1.33 billion. Analysts maintain a "Hold" rating, eyeing an average target price of $22.54 for this leader in genetic testing and precision medicine.